Washington – US Biotechnology company Moderna has announced new clinical data on its bivalent COVID-19 booster platform including data on the Company’s first bivalent booster candidate, mRNA-1273.211. Stéphane Bancel, Chief Executive Officer of Moderna, said: “The results validate our bivalent strategy, which we announced and began pursuing in February 2021. The results indicate that mRNA-1273.211 at the 50-µg dose level induced higher antibody responses than the 50-µg mRNA-1273 booster, even when additional variants of concern were not included in the booster vaccine.”
